Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $123.6 million versus the consensus estimate of $119.71 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.